drugset

drugset / Trial / NCT00127478

A Long Term Safety Study With Atrasentan

NCT00127478 ↗

Phase 2/3 Completed 166 enrolled Abbott

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.

Timeline

Start: 2001-07
Primary completion: —
Completion: 2007-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atrasentan	Other / unclassified	10 mg	—

Indications